Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Receives Consensus Rating of “Hold” from Analysts

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) has earned an average recommendation of “Hold” from the five ratings firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $38.3333.

A number of research analysts have recently commented on PHAR shares. Zacks Research upgraded Pharming Group from a “strong sell” rating to a “hold” rating in a research note on Friday, April 10th. HC Wainwright restated a “buy” rating and set a $37.00 price objective on shares of Pharming Group in a research report on Tuesday, March 24th. Weiss Ratings cut Pharming Group from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, May 11th. Canaccord Genuity Group assumed coverage on Pharming Group in a research report on Friday, April 10th. They issued a “buy” rating and a $37.00 target price for the company. Finally, Wall Street Zen lowered Pharming Group from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th.

Hedge Funds Weigh In On Pharming Group

Several large investors have recently modified their holdings of the business. EverSource Wealth Advisors LLC bought a new stake in shares of Pharming Group in the second quarter worth $32,000. SmartHarvest Portfolios LLC acquired a new position in Pharming Group during the 4th quarter worth about $224,000. Millennium Management LLC bought a new stake in shares of Pharming Group in the 4th quarter valued at about $360,000. Finally, NewEdge Advisors LLC grew its position in shares of Pharming Group by 11,310.3% in the 4th quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock valued at $510,000 after buying an additional 28,615 shares during the last quarter. Institutional investors own 0.03% of the company’s stock.

Pharming Group Price Performance

Shares of NASDAQ:PHAR opened at $13.47 on Friday. The company has a market cap of $951.25 million, a price-to-earnings ratio of 84.19 and a beta of -0.04. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.63 and a quick ratio of 2.06. The firm has a 50 day simple moving average of $13.12 and a 200 day simple moving average of $15.55. Pharming Group has a one year low of $9.54 and a one year high of $21.34.

Pharming Group (NASDAQ:PHAR) last issued its earnings results on Thursday, May 7th. The company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.12). The company had revenue of $72.45 million during the quarter, compared to analyst estimates of $92.06 million. Pharming Group had a net margin of 3.30% and a return on equity of 4.64%. Research analysts predict that Pharming Group will post 0.6 earnings per share for the current fiscal year.

Pharming Group Company Profile

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.